+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective



Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective



Expert Review of Anti-Infective Therapy 10(12): 1393-1404



Dissemination of carbapenemase-producing Klebsiella pneumoniae (CP-Kp) has caused a public health crisis that can be paralleled with that caused by the spread of MRSA. CP-Kps, being multidrug-resistant, mainly affect patients with severe underlying conditions in the acute-healthcare setting. CP-Kps are responsible for a variety of life-threatening infections including bacteremia and pneumonia. The shortage of therapeutic options has forced clinicians to use colistin as well as tigecycline, a novel bacteriostatic agent. Although both drugs are generally active in vitro against CP-Kps, therapeutic failures, especially in bacteremias, are quite common. The authors suggest here, after reviewing the literature, that use of the latter drugs should be re-assessed and optimized. The authors have also summarized experimental and clinical data indicating that exploitation of the pharmacokinetic/pharmacodynamic features of carbapenems may provide solutions in bloodstream infections caused by CP-Kps with low-level resistance to the latter drugs. Most importantly, there is evidence that monotherapy must be avoided.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051837787

Download citation: RISBibTeXText

PMID: 23253318

DOI: 10.1586/eri.12.138


Related references

Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae at a Hematology Department in Wenzhou, China. Internal Medicine 55(15): 2087-2091, 2017

Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clinical Infectious Diseases 55(7): 943-950, 2013

Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan. American Journal of Infection Control 37(2): 121-126, 2009

Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by Klebsiella pneumoniae Carbapenemase-Producing Klebsiella pneumoniae. Open Forum Infectious Diseases 5(4): Ofy054, 2018

A shorter period of therapy is associated with higher mortality in bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae in a Brazilian centre. Infectious Diseases 50(2): 156-161, 2017

Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infection Control and Hospital Epidemiology 31(12): 1250-1256, 2011

Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae among intensive care unit patients after orthotopic liver transplantation: risk factors for infection and impact of resistance on outcomes. Transplantation Proceedings 46(9): 3216-3218, 2015

Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrobial Agents and ChemoTherapy 58(4): 2322-2328, 2014

Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases. International Journal of Antimicrobial Agents 47(4): 335-339, 2016

Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrobial Agents and ChemoTherapy 48(10): 3720-3728, 2004

Increased relative abundance of Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae within the gut microbiota is associated with risk of bloodstream infection in long-term acute care hospital patients. Clinical Infectious Diseases 2018, 2018

Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clinical Infectious Diseases 56(5): 697-700, 2013

Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infection Control and Hospital Epidemiology 25(10): 860-867, 2004

Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrobial Agents and ChemoTherapy 50(2): 498-504, 2006

Infections Caused by Carbapenemase-Producing Klebsiella pneumoniae: Microbiological Characteristics and Risk Factors. Microbial Drug Resistance 2019, 2019